1. Home
  2. AKBA vs HBB Comparison

AKBA vs HBB Comparison

Compare AKBA & HBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$22.31

Market Cap

252.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
HBB
Founded
2007
1904
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
252.9M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
AKBA
HBB
Price
$1.23
$22.31
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
4.1M
41.3K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
2.38%
EPS Growth
93.94
N/A
EPS
N/A
0.26
Revenue
N/A
$606,852,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$83.92
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$12.72
52 Week High
$3.81
$25.05

Technical Indicators

Market Signals
Indicator
AKBA
HBB
Relative Strength Index (RSI) 46.66 53.01
Support Level $1.16 $18.15
Resistance Level $1.52 $24.44
Average True Range (ATR) 0.07 1.38
MACD -0.02 -0.07
Stochastic Oscillator 7.59 43.04

Price Performance

Historical Comparison
AKBA
HBB

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.

Share on Social Networks: